From January 2020, the world has been facing a catastrophic outbreak of coronavirus disease 2019 (CoViD-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [@b0005].

Available epidemiologic data suggest that a significant association with worse outcomes was seen in people with comorbidities [@b0010], the most prevalent of which are hypertension, cardiovascular disease, and diabetes.

Specifically, a couple of mechanisms have been hypothesized that might explain the link between CoViD-19 infection and diabetes, namely the regulation of expression of the Angiotensin-converting-enzyme 2 (ACE2) which has been identified as the receptor for the coronavirus spike protein, and the involvement of the dipeptidyl peptidase-4 (DPP-4) enzyme, which is commonly targeted pharmacologically in people with type 2 diabetes [@b0015], [@b0020], [@b0025]. The clinical relevance of these mechanisms is currently uncertain, but as a matter of fact diabetes is considered a risk factor for the development of severe pneumonia and a septic course due to virus infections [@b0030], and the same findings have been reported in case of CoViD-19 [@b0035]. This has led to a number of papers recently published and aimed at providing practical management recommendations for patients with diabetes during the CoViD-19 outbreak [@b0040], [@b0045].

Italy has been one of the earliest and most heavily involved countries in the CoViD-19 pandemic. Internal Medicine (IM) wards, present in all italian hospitals, have redesigned their healthcare delivery, and played a pivotal role in contrasting the spread of SARS-Cov2 [@b0050]. Due to their ubiquitous distribution, the IM departments and the relevant scientific societies, such as The Federation of Hospital Internists (FADOI) with about 3000 members working in more than 500 departments all over Italy, represent an observatory of particular importance to describe the burden of diabetes in the context of CoViD-19.

To assess how internists contributed during the first two more intense months of the CoViD-19 outbreak, FADOI submitted a brief questionnaire to a group of its members acting as Head of IM units, from north to south Italy. The questionnaire included several questions investigating IM activities and its involvement in the pandemia, and particular attention was paid to patients with diabetes, the relevant comorbidities, the antidiabetic drugs used during hospitalization and patient outcome.

Fifty-two IM units participated to the survey, and 38 of them were placed in CoVid Hospitals. In this setting, fifty-eight percent of beds dedicated to CoViD patients in CoViD Hospitals were in charge of IM units, and globally cared for 6650 patients during the period March 15-April 30, 2020. Of these patients, 1264 (19%) had diabetes. The percentage distribution of the main comorbidities among patients with diabetes, and of the main categories of antidiabetic dugs used is shown in [Table 1](#t0005){ref-type="table"} . Mortality rate in CoViD patients with or without diabetes were 20.5% and 14%, respectively (p \< 0.001).Table 1Comorbidities and drugs used in diabetic patients with CoViD-19.VariableCohort***Comorbidity:***Arterial hypertension69.9%Heart failure47.0%Obesity32.5%Renal insufficiency25.3%COPD22.9%***Drugs used:***Insulin97.1%Metformin34.3%DPP4-i20.1%GLP1-RA14.3%Sulphonylureas\
5.7%\
SGLT2-i5.4%Repaglinide2.9%

Our survey seems to confirm that type 2 diabetes is a major comorbidity of CoViD-19. However, the percentage of patients with diabetes that we observed among those with CoViD-19 is not higher than figures of patients with diabetes hospitalized in IM wards in Italy before the outbreak. Therefore, this finding does not support an increased incidence of CoViD-19 infection in people with diabetes, as previously reported [@b0040].

On the other side, in our cohort patients with diabetes appeared at a significantly increased risk of worse outcome if compared with patients without diabetes. There are several hypotheses to explain this finding: these include defects in innate immunity, and the fact the diabetes is often combined with cardiovascular disease and overweight/obesity, which per se could help to explain the association with fatal outcomes of CoViD-19 [@b0040]. The role of cardiovascular comorbidities and obesity seems to be confirmed by the high percentages found in the population of diabetes patients considered in our survey.

The complex clinical condition of patients with diabetes diagnosed with SARS-CoV-2 infection may bear challenges for the use of most diabetes medications. For some of them, concerns have been raised that they could increase the number of ACE2 receptors on the cells utilized by SARS-CoV-2 for penetration, however no evidence presently exists that shows that any specific antidiabetic drugs may be harmful in terms of acquiring or worsening CoViD-19 [@b0045].

Moreover, it is important to underline the high insulin requirement in patients with a severe course of the infection [@b0040], and that achieving glycemic targets can improve outcomes in patients with CoViD-19 [@b0055], [@b0060], [@b0065]. Our findings, and namely a significantly higher percentage of patients treated with insulin than previously reported in the setting of italian IM wards before the outbreak [@b0070], and a not negligible use of DPP4-i, seem coherent with some suggestions from literature [@b0020], [@b0040].

In conclusion, the significant relative weight of the IM units in the management of patients with CoViD-19 and the number of patients considered in our analysis, probably make our observatory of interest and worth considering for the scientific community. Our experience seems to suggest that some aspects related to a possible greater predisposition of patient with diabetes to CoVid-19 should be furtherly elucidated.Moreover, confirmation that patients with diabetes and CoViD-19 have a more severe outcome than non-diabetic patients, underlines the importance of paying special attention to this patient population and its management [@b0075].
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